Midodrine Duration of Therapy for Orthostatic Hypotension
Midodrine does not have a defined maximum duration in prescribing information. Therapy should be continued only if significant symptomatic improvement is maintained. [1]
Continuation Criteria During Ongoing Therapy
Midodrine should be continued only for patients who report significant symptomatic improvement after initiation. [1]
Discontinuation Triggers
Midodrine should be stopped if supine blood pressure increases excessively. [1] Midodrine should be discontinued immediately if supine hypertension persists. [1]
Monitoring Requirements Affecting How Long Therapy Can Continue
Supine and sitting blood pressure should be monitored regularly in patients maintained on midodrine. [1] Evaluation of supine hypertension should occur at the beginning of therapy. [1]
Evidence on Persistence and Stopping Patterns
In a real-world study of orthostatic hypotension treatment use, discontinuation of midodrine occurred in a substantial proportion of patients over follow-up, supporting frequent treatment reassessment in practice. [2]
Evidence Gaps for Long-Term Treatment
Long-term efficacy and safety of midodrine remain unclear because key trials supporting use were short in duration. [3]
Practical Implication for “How Long” Therapy Can Be Used
The duration of midodrine therapy should be individualized based on sustained symptomatic benefit and the ability to prevent or control supine hypertension, with ongoing reassessment and discontinuation when benefit is not maintained or risk is unacceptable. [1][2]